Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
It is not exactly news that men who are diagnosed with localized prostate cancer, but who have a significant number of comorbid conditions, are actually at relatively low risk of prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: outcome, PCSM, prognosis, prostate cancer-specific mortality, questionnaire, survey, TIBI-CaP | 5 Comments »
It has been known for a while that statins and nonsteroidal anti-inflammatory drugs (NSAIDs) can affect PSA levels. A new paper now opens the question of whether men who take these and/or other drugs for significant time periods are at risk for a “missed” diagnosis of prostate cancer.
Filed under: Diagnosis, Risk | Tagged: diuretic, NSAID, PSA, risk, statin | 3 Comments »
The potential to use magnetically charged nanoparticles as a method to treat a variety of forms of cancer by using the particles to heat and kill tumor cells has been around for several years now. Apparently we are getting a little closer to the application of this technology in the treatment of prostate cancer.
Filed under: Management | Tagged: magnetic, nanoparticles, nanotechnology | 1 Comment »
Figitumumab (also known as CP-751,871) is a fully humanized monoclonal antibody designed to target the insulin-like growth factor type 1 receptor (IGF-IR). Data are now available from a very early-stage trial of figitumumab in combination with docetaxel in the treatment of patients with late-stage solid tumors — including castration-resiatant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: 871, castration-resistant prostate cancer, CP-751, CRPC, figitumumab | Leave a Comment »
An article still to be formally published in European Urology provides data on the outcomes of 803 patients with localized prostate cancer, all treated with high-intensity focused ultrasound (HIFU) between 1993 and 2007 at six centers in France.
Filed under: Management, Treatment, Uncategorized | Tagged: HIFU, high-intensity focused ultrasound, localized, outcome | 10 Comments »
A newly published report provides initial information from a pilot study on the feasibility of laser dissection of the neurovascular bundles (NVBs) during robot-assisted laparoscopic prostatectomy (RALP) as a treatment for localized prostate cancer.
Filed under: Management, Treatment | Tagged: laser, neurovascular bundle, NVB, RALP | 1 Comment »
Atul Gawande is a general surgeon who practices in New York. He also writes regularly on issues related to the relationship between medicine and society.
Filed under: Management | Tagged: choices, death, Gawande, hope, life, love | 1 Comment »
Researchers at Columbia University are reporting that a complex mixture of 33 different nutrients, medicinal mushrooms, minerals, and herbs seems to have significant activity affecting the growth and survival of androgen-dependent and androgen-independent prostate cancer cells lines derived from mice and humans.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, nutritional supplement, PectaSol, ProstaCaid | 3 Comments »
The use of androgen deprivation therapy (ADT) is at the heart of treatment for patients with advanced forms of prostate cancer. What has been debated for years, however, is when, for how long, and in combination with what other forms of therapy ADT should be applied.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, androgen deprovation therapy, local therapy, locally advanced, outcome | 9 Comments »
A new report from the prostate cancer research team at Johns Hopkins has offered data suggesting a strong association between the structure of the nucleus of prostate cancer cells in individual patients and the risk for more aggressive prostate cancer. The report is based on data with a follow-up time of up to 25 years.
Filed under: Diagnosis, Management, Risk | Tagged: NRV, nuclear roundness, prognosis, variance | 5 Comments »
The staging systems used by clinicians and pathologists for assignment of the stage of prostate cancer were all developed more than 20 years ago, and have seen only relatively minor adjustments since the introduction of the PSA test.
Filed under: Diagnosis, Management, Risk | Tagged: clinical stage, Diagnosis, prognosis, relevance, staging | 2 Comments »
In a somewhat surprising series of studies, a team of researchers at Purdue University and the Indiana University School of Medicine have demonstrated that cholesterol sulfate has high potential as a marker for prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: cholesterol, marker, sulfate | 6 Comments »
A large study of genetic markers in Japanese prostate cancer patients has clearly shown that some of the markers of prostate cancer in Caucasians do not appear in Japanese patients whereas new markers appear to be common among Japanese.
Filed under: Diagnosis, Risk | Tagged: association, genetics, genome, SNP | Leave a Comment »
A story in the Boston Globe this morning documents two cases in which prostate biopsy results given to a specific patient were inaccurate because the wrong patient data was provided by a pathology laboratory.
Filed under: Diagnosis, Management, Risk | Tagged: error, laboratory, medical | 1 Comment »
One of our regular readers has suggested we comment on a recent paper questioning the need for annual, lifelong PSA testing after radical prostatectomy for patients treated for low-risk prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: annual, follow-up, low risk, PSA, radical prostatectomy | 7 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site